Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

DiaMedica Therapeutics (DMAC) stock in plain English

Free brief · no signupStart here
DMACPublished Nov 8, 2026
DiaMedica Therapeutics Inc
Healthcare · Biotechnology
Develops synthetic protein therapies to treat acute ischemic stroke and chronic vascular conditions. Runs clinical trials for its lead candidate to improve organ blood flow.
Assets:
DM199 protein candidateSynthesizes recombinant human tissue kallikrein-1
ReMEDy2 trialEvaluates stroke patients in Phase 2 and 3 studies
Minneapolis headquartersCoordinates clinical trial operations and drug research
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

74
OPS ScoreOperating finances
Latest quote
-6.64%$8.02
$432.73M
n/a
-

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 08, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was DMAC. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does DiaMedica Therapeutics (DMAC) do?

DiaMedica Therapeutics Inc (DMAC) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops synthetic protein therapies to treat acute ischemic stroke and chronic vascular conditions. Runs clinical trials for its lead candidate to improve organ blood flow. It is worth $432.73M on the market.

Market cap
$432.73M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 08, 2026

DMAC’s flags, in plain English

Each flag is a number from DiaMedica Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 08, 2026.

Stupid Cash

Can pay this year's bills 4.8 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 1% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Insiders Hold

Insiders own 43.3% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Heavily Shorted

16.4% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.

1 more risk note open with the free trial. Try it free for 7 days.

Questions about DMAC

How big is DiaMedica Therapeutics?

DiaMedica Therapeutics’ market cap is $432.73M: what all of its shares are worth together at today’s price.

What could go wrong with DMAC?

The company generates zero product revenue and relies on equity financing to fund clinical trials. That is one risk on DiaMedica Therapeutics’ card. Its first risk flag is Heavily Shorted, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From DiaMedica Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. DMAC’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card